Jeito Capital renforce son soutien à Pulmocide en participant à un nouveau financement de 52 millions de dollars
December 06, 2022 07:00 ET
|
Jeito Capital
Jeito Capital renforce son soutien à Pulmocide en participant à un nouveau financement de 52 millions de dollars Ce nouveau tour de table permettra d’accélérer le développement clinique et...
Jeito Capital strengthens its support in Pulmocide with participation in $52 million financing
December 06, 2022 07:00 ET
|
Jeito Capital
Jeito Capital strengthens its support in Pulmocide with participation in $52 million financing The Series C extension round will...
Jeito Capital affirme son leadership dans le secteur biopharmaceutique européen avec la cession de Neogene Therapeutics à AstraZeneca
November 29, 2022 02:22 ET
|
Jeito Capital
Jeito Capital affirme son leadership dans le secteur biopharmaceutique européen avec la cession de Neogene Therapeutics à AstraZeneca ...
Jeito Capital demonstrates European biopharma leadership with first exit with AstraZeneca acquisition of Neogene Therapeutics
November 29, 2022 02:19 ET
|
Jeito Capital
Jeito Capital demonstrates European biopharma leadership with first exit with AstraZeneca acquisition of Neogene Therapeutics Deal...
Jeito Capital co-leads EUR 50 million financing in CatalYm, a clinical-stage biopharma company developing novel immunotherapies for patients with cancer
November 22, 2022 05:00 ET
|
Jeito Capital
Jeito Capital co-leads EUR 50 million financing in CatalYm, a clinical-stage biopharma company developing novel immunotherapies for patients...
Jeito Capital investit dans CatalYm Jeito Capital investit dans CatalYm société biopharmaceutique allemande spécialisée en immuno-oncologie
November 22, 2022 05:00 ET
|
Jeito Capital
Jeito Capital investit dans CatalYm société biopharmaceutique allemande spécialisée en immuno-oncologie Jeito Capital co-dirige un financement de série C de 50 millions d'euros avec Brandon...
Jeito Capital réalise son 1er investissement aux Etats-Unis avec HI-Bio, biopharma spécialisée dans la médecine de précision des maladies auto-immunes
November 01, 2022 09:05 ET
|
Jeito Capital
Jeito Capital réalise son 1er investissement aux Etats-Unis avec HI-Bio, biopharma spécialisée dans la médecine de précision des maladies...
Jeito Capital becomes a significant investor in HI-Bio, a clinical-stage biotech company developing targeted therapies for patients with severe immune-mediated diseases
November 01, 2022 06:02 ET
|
Jeito Capital
Jeito Capital becomes a significant investor in HI-Bio, a clinical-stage biotech company developing targeted therapies for patients with...
Jeito Capital co-leads EUR 80 million Series B financing in European oncology company, Precirix
March 16, 2022 03:00 ET
|
Jeito Capital
Jeito Capital co-leads EUR 80 million Series B financing in European oncology company, Precirix Jeito Capital chooses Precirix, a clinical-stage biotechnology company developing precision...
Jeito Capital co-leads $65 million Series A financing in EyeBio
February 22, 2022 05:01 ET
|
Jeito Capital
Jeito Capital co-leads $65 million Series A financing in EyeBio EyeBio is a newly launched global company developing the next generation of eye disease therapiesFounded by two pioneers in...